Southwest Oncology Group Biorepository

西南肿瘤集团生物样本库

• 批准号: 8752275
• 负责人: CHARLES D. BLANKE
• 金额: $ 63.07万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-25 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8752275
• 关键词: Address; Cancer Control; Clinical; Clinical Research; Clinical Trials; Collaborations; Collection; Communication; Communities; DNA; Development; Funding; Goals; Human; Individual; Informatics; Institution; Laboratories; Malignant Neoplasms; Marketing; Molecular; Nucleic Acids; Pathologist; Patient Representative; Phase III Clinical Trials; Pilot Projects; Policies; Population Group; Population Heterogeneity; Prevention; Procedures; Process; RNA; Research; Research Infrastructure; Research Personnel; Resistance; Sampling; Science; Serum; Site; Source; Southwest Oncology Group; Specimen; Specimen Handling; Staging; Tissues; Training Programs; Translations; Tumor Bank; Work; base; biobank; data sharing; improved; insight; multidisciplinary; novel therapeutics; operation; patient population; prognostic; repository; statistical center; therapeutic target

DESCRIPTION (provided by applicant): The overall general goals of the Southwest Oncology Group Biospecimen Repository is to support the increased collection of, storage of and access to high-quality, well-annotated human specimens collected from and representative of the patient populations entered into NCI-funded clinical trials. The overall scientific goal in providing this infrastructure is to develop improved prognostic and predictive markers for cancer, to improve molecular staging, to understand mechanisms of treatment resistance, to identify new putative therapeutic targets, and to develop novel therapeutic strategies. These goals are addressed through broad-based multidisciplinary efforts that rely on access to high quality, well characterized biospecimens from diverse population groups and that bring together clinical, laboratory and scientific expertise from within SWOG membership and its affiliates, as well as from individuals outside of SWOG. These activities critically rely on talented investigators, pathologists, biospecimen banks and close working relationships of the biorepository with the submitting institutions, the Operations Office, Statistical Center, investigators and the NCI. Specimens will be released based on the scientific merit of the proposals received via SWOG Translation Science Review process.

描述（由申请人提供）：西南肿瘤学组生物样本库的总体目标是支持更多地收集、存储和获取高质量、注释明确的人类样本，这些样本是从参加 NCI 资助的临床试验的患者群体中收集并代表的。提供这一基础设施的总体科学目标是开发改进的癌症预后和预测标记物，改善分子分期，了解治疗耐药机制，确定新的假定治疗靶点，并开发新的治疗策略。这些目标是通过基础广泛的多学科努力来实现的，这些努力依赖于从不同人群获取高质量、特征明确的生物样本，并汇集了 SWOG 成员及其附属机构以及 SWOG 以外个人的临床、实验室和科学专业知识。这些活动很大程度上依赖于才华横溢的研究人员、病理学家、生物样本库以及生物样本库与提交机构、运营办公室、统计中心、研究人员和 NCI 的密切工作关系。样本将根据通过 SWOG 翻译科学审查流程收到的提案的科学价值进行发布。